Navigation Links
Immtech Announces Posting of Annual Shareholders Meeting Presentation
Date:11/29/2007

NEW YORK, Nov. 29 /PRNewswire-FirstCall/ -- Immtech Pharmaceuticals, Inc. (Amex: IMM) announced that the presentation to be made during the annual shareholders meeting will be posted on the Company's website, http://www.immtechpharma.com, prior to the meeting.

About Immtech Pharmaceuticals, Inc.

Immtech Pharmaceuticals, Inc. is focused on developing and commercializing drugs to treat infectious diseases. Immtech has advanced clinical programs that include new treatments for Pneumocystis pneumonia (PCP), malaria, and trypanosomiasis (African sleeping sickness), and a well defined, expanding library of compounds targeting Hepatitis C, fungal infections, and bacterial infections. Immtech holds exclusive worldwide licenses to certain patents, patent applications and technology for products derived from a proprietary pharmaceutical platform. For additional information, please go to http://www.immtechpharma.com.

"Safe Harbor" Statement under the Private Securities Reform Act of 1995: Statements in this press release regarding Immtech Pharmaceuticals, Inc.'s business, including the future prospects for PCP, which are not historical facts are "forward-looking statements" that involve risks and uncertainties. Actual results could differ materially from these forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed under the headings "Management's Discussion and Analysis of Financial Condition and Results of Operations" and "Risk Factors" in Immtech's annual report on Form 10-K for the year ended March 31, 2007 and in
'/>"/>

SOURCE Immtech Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2

Related medicine technology :

1. General Wesley Clark Joins Immtech as Consulting Strategic Advisor
2. US FDA Grants Orphan Drug Status to Immtechs Pafuramidine for Treatment of African Sleeping Sickness
3. Chinese SFDA Grants Immtech Fast Track Status
4. Immtech Announces Interim Analysis in Phase III African Sleeping Sickness Trial
5. Immtech Receives $5.1 Million to Further African Sleeping Sickness Clinical Trials
6. Immtech to Present at The Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
7. Immtech Reports Fiscal Second Quarter 2008 Results
8. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
9. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
10. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
11. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)...ewswire/--AccordingtoMillenniumResearchGroup(MRG),...gence,thenearly$3billionUSmarketfortraumafixationd...earsdespitetherecenteconomicslowdown.MRG,s USMarke...willremainhighlydynamicoverthenextfiveyears,withco...underservedsegmentsofthetraumafixationmarket,fueli...
(Date:11/25/2009)...OHANNESBURG,November25/PRNewswire/--,iThembaPharma...dtoday,thattheyhavesignedacollaborativeagreementto...,sworldclasscomputationalchemistryandleaddiscovery...ntoprovidemedicinaland,syntheticchemistrysupportto...tnetwork.iThembaPharmaceuticalsandPyxisDiscovery,a...
(Date:11/24/2009)...ewswire-FirstCall/--Endologix,Inc.(Nasdaq: ELGX ),...orders,announcedtodaythatithasfiledamotiontostay,o...lawsuitbroughtagainstitinOctober2009byCook,Inc.The...anapolis,Indiana. ,, Endologixhasrequestedthatt...rademarkOffice(USPTO)conductsproceedingstore-exami...
Breaking Medicine Technology:US Trauma Fixation Device Market Not Seeing Signs of Slowdown 2US Trauma Fixation Device Market Not Seeing Signs of Slowdown 3iThemba Pharmaceuticals (Pty) Ltd and Pyxis Discovery B.V. Announce Collaborative Agreement to Offer a Combined Service Offering 2Endologix Files Motion to Discontinue Court Proceedings Related to Alleged Patent Infringement 2AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH Receptor Targeted Cytotoxic Conjugate AEZS 108 in Endometrial Cancer 14959 1AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH Receptor Targeted Cytotoxic Conjugate AEZS 108 in Endometrial Cancer 14959 2AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH Receptor Targeted Cytotoxic Conjugate AEZS 108 in Endometrial Cancer 14959 3AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH Receptor Targeted Cytotoxic Conjugate AEZS 108 in Endometrial Cancer 14959 4Genomic Health to Present at Piper Jaffray Health Care Conference 14955 1Genomic Health to Present at Piper Jaffray Health Care Conference 14955 2Satellite Healthcare and Renal Disease Survivor Elias Nasrallah Join Forces to Support the Homeless This Holiday Season 6501 1Satellite Healthcare and Renal Disease Survivor Elias Nasrallah Join Forces to Support the Homeless This Holiday Season 6501 2
...5 Million Interferon-Beta-CTP Development Program ...a Special Grant From the Israeli Office of the ...NA, Israel, Aug. 5 Modigene Inc. (OTC,Bulletin Bo...&D subsidiary,has received approval for a special ...st ("OCS") in support of the company,s development...
...-Term Clinical Study Confirms Effectiveness of Aut...he results of a two-year,representative study of k...ly renowned journal "Osteoarthritis and Cartilage"...e therapy, in which,anti-inflammatory proteins obt...to the arthritic joint., Researchers at Heinrich ...
Other Medicine Technology:Modigene Awarded Israeli Government Grant to Support Development of Its Longer-Acting Interferon Beta 2Modigene Awarded Israeli Government Grant to Support Development of Its Longer-Acting Interferon Beta 3Modigene Awarded Israeli Government Grant to Support Development of Its Longer-Acting Interferon Beta 4Orthokine Treatment is Effective for Knee Arthritis, Even After Two Years 2
(Date:11/25/2009)...rological symptoms, study finds , , WED...ide effects are among the potential problems faced...ere treated with cisplatin-based chemotherapy, a n...Norwegian men treated for unilateral testicular ca...ow-up survey conducted from 1998 to 2002. , The...
(Date:11/25/2009)...ire/-- MISSIONSkincare ®isproudtosupportGNC,s...GNC,sannualSt.Jude ThanksandGiving campaign,$1from...PER-C(TM)LipBalm willbedonatedtoSt.Jude.Additional...donationatcheckoutatoneoftheir5,000+retaillocation....Judeduringtheir2009 ThanksandGiving campaign. ,...
(Date:11/25/2009)...wnforthe4thStraightYear ,, WASHINGTON,Nov.25/...-Georgia(LCA-GA)issuedthe 4thAnnualReportCardonLun...deagainstthislethaldiseaseinthestateofGeorgia.LCA-...nalorganizationdedicatedexclusivelytopatientsuppor...er. ,, (Logo: http://www.newscom.com/cgi-bin/pr...
(Date:11/25/2009)...tal cancer also can reverse a rare stomach disorde...the disease, researchers at Vanderbilt University ...ase causes thickening of the stomach lining, sever...anemia and swelling in the feet and ankles due to ...astric cancer. Previously, the only effective trea...
(Date:11/25/2009)...e skin kill tumor cells, study finds , ,...accine delivered in a fingernail-size implant elim...s. , The method uses polymer disks, 8.5 millime...fic antigens and implanted under the skin to repro...rd University scientists who developed the implant...
Breaking Medicine News(10 mins):Health News:MISSION Skincare(R) Supports GNC's Efforts To Raise Money for St. Jude Children's Research Hospital(R) 2Health News:Lung Cancer Alliance-Georgia Issues 4th Annual State-Specific Report Card on Lung Cancer 2Health News:Vanderbilt scientists report first effective medical therapy for rare stomach disorder 2
...pulmonary syndrome (HPS) develops when an arterial...ary vascular dilatations that are often associated... of patients with liver cirrhosis undergoing evalu...ly in those with decompensated liver disease. , ...
... lead to better smoking-cessation aids , WEDNESDAY...e brain show increased activation in smokers who a...sylvania study. , The finding may boost understan...n imaging studies showing how subjects respond to ...
.... 18 Kids want help from adults,as they face a da...ectures,only scare them away. ethiKids, inc. intro...ns open during the formative pre-teen years., On ...nges related to values and skills development. Its...
...nal Association joins LaSalle as a lender under th... SANTA ANA, Calif., Dec. 18 Grubb & Ellis,Healthc...ecured revolving,line of credit with LaSalle Bank ...ion to $80,million. The line of credit is for a te...
...ts Home Front Needs of Families with Deployed Serv...FT. RICHARDSON, Alaska, Dec. 18 TriWest Healthcar...onal Guard Officer,s,Auxiliary - Friends of the Gu...president for the Alaska area at TriWest,will pres...
...nn., Dec. 18 Cumberland Pharmaceuticals is,please...ives., David L. Lowrance has been promoted to Vic...ole, he is responsible for overseeing the,company,...oining Cumberland in 2003 as Director of Finance,a...
Other Medicine News:Health News:Who is the arch-criminal in the development of hepatopulmonary syndrome? 2Health News:Smokers' Brain Centers Activate During Nicotine Cravings 2Health News:ethiKids, inc. Launches Website and Products to Address Declining Ethics in Children 2Health News:Grubb & Ellis Healthcare REIT Increases Line of Credit With LaSalle Bank to $80 Million 2Health News:Grubb & Ellis Healthcare REIT Increases Line of Credit With LaSalle Bank to $80 Million 3Health News:TriWest Contributes $12,000 to Alaska National Guard Fund 2Health News:Cumberland Pharmaceuticals Announces Appointments 2
... Laboratories is a national reference laboratory a...earch and development. ARUP offers an extensive te... in clinical and anatomic pathology. Owned by the ...lude more than half of the nation's university tea...
... Laboratories is a national reference laboratory a...earch and development. ARUP offers an extensive te... in clinical and anatomic pathology. Owned by the ...lude more than half of the nation's university tea...
... Laboratories is a national reference laboratory a...earch and development. ARUP offers an extensive te... in clinical and anatomic pathology. Owned by the ...lude more than half of the nation's university tea...
... Laboratories is a national reference laboratory a...earch and development. ARUP offers an extensive te... in clinical and anatomic pathology. Owned by the ...lude more than half of the nation's university tea...
Medicine Products: